Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
Alessandro Rizzo, Angela Dalia Ricci, Nastassja Tober, et al.
Anticancer Research (2020) Vol. 40, Iss. 6, pp. 3013-3030
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Recent advances of immunotherapy for biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Review of Gastroenterology & Hepatology (2020) Vol. 15, Iss. 5, pp. 527-536
Closed Access | Times Cited: 116
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 4, pp. 317-324
Open Access | Times Cited: 84
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!”
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100335-100335
Open Access | Times Cited: 83
Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
Makoto Ueno, Masafumi Ikeda, Takashi Sasaki, et al.
BMC Cancer (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 81
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
Cancer Control (2020) Vol. 27, Iss. 3
Open Access | Times Cited: 80
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer
Alessandro Rizzo, Giovanni Brandi
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 5, pp. 547-554
Closed Access | Times Cited: 79
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100337-100337
Open Access | Times Cited: 77
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma
Helena Verdaguer, Tamara Saurí, Daniel Acosta, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 8, pp. 1662-1671
Open Access | Times Cited: 46
Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
Yamin Shu, Yufeng Ding, Xu‐Cheng He, et al.
Cancer Medicine (2022) Vol. 12, Iss. 3, pp. 3365-3375
Open Access | Times Cited: 45
Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges
Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, et al.
Current Oncology (2021) Vol. 28, Iss. 5, pp. 3393-3402
Open Access | Times Cited: 49
Nationwide treatment and outcomes of perihilar cholangiocarcinoma
Anne‐Marleen van Keulen, Stijn Franssen, Lydia G. van der Geest, et al.
Liver International (2021) Vol. 41, Iss. 8, pp. 1945-1953
Open Access | Times Cited: 43
MUC1 induces the accumulation of Foxp3+ Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway
Guofeng Zhang, Zheng Ge, Haipeng Zhang, et al.
International Immunopharmacology (2023) Vol. 118, pp. 110091-110091
Closed Access | Times Cited: 14
Sex disparity in clinical characteristics and long-term prognosis after liver resection for patients with intrahepatic cholangiocarcinoma: A propensity score matching analysis
Yiran Zou, Xin‐Fei Xu, Tanyang Wu, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e29910-e29910
Open Access | Times Cited: 5
Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma
Raluca Maria Fostea, Elisa Fontana, Gonzalo Torga, et al.
Cancers (2020) Vol. 12, Iss. 9, pp. 2599-2599
Open Access | Times Cited: 35
Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial
Shuiling Jin, Ruihua Zhao, Chuang Zhou, et al.
International Journal of Cancer (2022) Vol. 152, Iss. 8, pp. 1648-1658
Closed Access | Times Cited: 21
Exploring Zanidatamab’s efficacy across HER2-positive Malignancies: a narrative review
Warisha Kanwal, Kaneez Narjis, Sarah Musani, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Preoperative glasgow prognostic score was an effective prognostic indicator in patients with biliary tract cancer
Rongqiang Liu, Ling Wang, Jing Ye, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, et al.
Medicines (2020) Vol. 7, Iss. 9, pp. 54-54
Open Access | Times Cited: 28
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100356-100356
Open Access | Times Cited: 25
Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, et al.
Translational Oncology (2022) Vol. 25, pp. 101514-101514
Open Access | Times Cited: 18
Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching
Song Liu, Qingdong Wang, Yin Shunhang, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Comparing Immunotherapy Versus Chemotherapy Alone as Second-Line Therapy for Malignant Tumors of the Biliary Tract: A Retrospective Study
Chengzhi Jiang, Yang Liu, Ling-Dong Kong, et al.
Clinical Medicine Insights Oncology (2025) Vol. 19
Open Access
Triiodothyronine promotes the proliferation and chemoresistance of cholangiocarcinoma cells via HIF-1α/Glut1-stimulated glycolysis
Dihua Huang, Feng Xu, Luohang Xu, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 5, pp. 167814-167814
Closed Access
Identifying a unique chromosomal pattern to predict the gemcitabine response in patients with cholangiocarcinoma
Sutheemon Techa-Ay, Sasithorn Watcharadetwittaya, Raksawan Deenonpoe, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Preoperative total bile acid can be used as a prognostic biomarker in patients with operable biliary tract cancers
Shanshan Fan, Kexin Zhao, Jianfeng Lei, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top